Animal models have greatly enriched our understanding of the molecular mechanisms of numerous types of cancers. Gastric cancer is one of the most common cancers worldwide, with a poor prognosis and high incidence of drug-resistance. However, most inbred strains of mice have proven resistant to gastric carcinogenesis. To establish useful models which mimic human gastric cancer phenotypes, investigators have utilized animals infected with Helicobacter species and treated with carcinogens. In addition, by exploiting genetic engineering, a variety of transgenic and knockout mouse models of gastric cancer have emerged, such as INS-GAS mice and TFF1 knockout mice. Investigators have used the combination of carcinogens and gene alteration to accelerate gastric cancer development, but rarely do mouse models show an aggressive and metastatic gastric cancer phenotype that could be relevant to preclinical studies, which may require more specific targeting of gastric progenitor cells. Here, we review current gastric carcinogenesis mouse models and provide our future perspectives on this field.
References
[1]
Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917, doi:10.1002/ijc.25516.
[2]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90, doi:10.3322/caac.20107.
[3]
Kawase, S.; Ishikura, H. Female-predominant occurrence of spontaneous gastric adenocarcinoma in cotton rats. Lab. Anim. Sci. 1995, 45, 244–248.
[4]
Waldum, H.L.; R？rvik, H.; Falkmer, S.; Kawase, S. Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Lab. Anim. Sci. 1999, 49, 241–247.
[5]
Cui, G.; Qvigstad, G.; Falkmer, S.; Sandvik, A.K.; Kawase, S.; Waldum, H.L. Spontaneous ECLomas in cotton rats (Sigmodon hispidus): Tumours occurring in hypoacidic/hypergastrinaemic animals with normal parietal cells. Carcinogenesis 2000, 21, 23–27, doi:10.1093/carcin/21.1.23.
[6]
Koga, T.; Takahashi, K.; Sato, K.; Kikuchi, I.; Okazaki, Y.; Miura, T.; Katsuta, M.; Narita, T. The effect of colonisation by Helicobacter pylori in Praomys (Mastomys) natalensis on the incidence of carcinoids. J. Med. Microbiol. 2002, 51, 777–785.
[7]
Kumazawa, H.; Takagi, H.; Sudo, K.; Nakamura, W.; Hosoda, S. Adenocarcinoma and carcinoid developing spontaneously in the stomach of mutant strains of Mastomys natalensis. Virchows Arch. A Pathol. Anat. Histopathol. 1989, 416, 141–151, doi:10.1007/BF01606319.
[8]
Correa, P.; Haenszel, W.; Cuello, C.; Tannenbaum, S.; Archer, M. A model for gastric cancer epidemiology. Lancet 1975, 2, 58–60.
[9]
Saito, T.; Sugimura, T. Biochemical studies on carcinogenesis in the glandular stomach of rats with N-methyl-N'-nitro-N-nitrosoguanidine. Gann 1973, 64, 373–381.
[10]
Sugimura, T.; Fujimura, S. Tumour production in glandular stomach of rat by N-methyl-N'-nitro-N-nitrosoguanidine. Nature 1967, 216, 943–944, doi:10.1038/216943a0.
[11]
Tatematsu, M.; Ogawa, K.; Hoshiya, T.; Shichino, Y.; Kato, T.; Imaida, K.; Ito, N. Induction of adenocarcinomas in the glandular stomach of BALB/c mice treated with N-methyl-N-nitrosourea. Jpn. J. Cancer Res. 1992, 83, 915–918, doi:10.1111/j.1349-7006.1992.tb01999.x.
[12]
Marshall, B.J.; Warren, J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1, 1311–1315, doi:10.1016/S0140-6736(84)91816-6.
[13]
Forman, D.; Newell, D.G.; Fullerton, F.; Yarnell, J.W.; Stacey, A.R.; Wald, N.; Sitas, F. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 1991, 302, 1302–1305, doi:10.1136/bmj.302.6788.1302.
[14]
Nomura, A.; Stemmermann, G.N.; Chyou, P.H.; Kato, I.; Perez-Perez, G.I.; Blaser, M.J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 1991, 325, 1132–1136, doi:10.1056/NEJM199110173251604.
[15]
Parsonnet, J.; Friedman, G.D.; Vandersteen, D.P.; Chang, Y.; Vogelman, J.H.; Orentreich, N.; Sibley, R.K. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991, 325, 1127–1131, doi:10.1056/NEJM199110173251603.
[16]
Uemura, N.; Okamoto, S.; Yamamoto, S.; Matsumura, N.; Yamaguchi, S.; Yamakido, M.; Taniyama, K.; Sasaki, N.; Schlemper, R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345, 784–789, doi:10.1056/NEJMoa001999.
[17]
Fox, J.G.; Wang, T.C. Helicobacter pylori—Not a good bug after all! N. Engl. J. Med. 2001, 345, 829–832, doi:10.1056/NEJM200109133451111.
[18]
Lee, A.; Hazell, S.L.; O’Rourke, J.; Kouprach, S. Isolation of a spiral-shaped bacterium from the cat stomach. Infect. Immun. 1988, 56, 2843–2850.
[19]
Rogers, A.B.; Taylor, N.S.; Whary, M.T.; Stefanich, E.D.; Wang, T.C.; Fox, J.G. Helicobacter pylori but not high salt induces gastric intraepithelial neoplasia in B6129 mice. Cancer Res. 2005, 65, 10709–10715, doi:10.1158/0008-5472.CAN-05-1846.
[20]
Lee, A.; O'Rourke, J.; de Ungria, M.C.; Robertson, B.; Daskalopoulos, G.; Dixon, M.F. A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain. Gastroenterology 1997, 112, 1386–1397, doi:10.1016/S0016-5085(97)70155-0.
[21]
Fox, J.G.; Sheppard, B.J.; Dangler, C.A.; Whary, M.T.; Ihrig, M.; Wang, T.C. Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res. 2002, 62, 696–702.
[22]
Fanning, E.; Knippers, R. Structure and function of simian virus 40 large tumor antigen. Annu. Rev. Biochem. 1992, 61, 55–85, doi:10.1146/annurev.bi.61.070192.000415.
[23]
Montag, A.G.; Oka, T.; Baek, K.H.; Choi, C.S.; Jay, G.; Agarwal, K. Tumors in hepatobiliary tract and pancreatic islet tissues of transgenic mice harboring gastrin simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 1993, 90, 6696–6700.
[24]
Thompson, J.; Epting, T.; Schwarzkopf, G.; Singhofen, A.; Eades-Perner, A.M.; van der Putten, H.; Zimmermann, W. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. Int. J. Cancer 2000, 86, 863–869, doi:10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4.
[25]
Li, Q.; Karam, S.M.; Gordon, J.I. Simian virus 40 T antigen-induced amplification of pre-parietal cells in transgenic mice. Effects on other gastric epithelial cell lineages and evidence for a p53-independent apoptotic mechanism that operates in a committed progenitor. J. Biol. Chem. 1995, 270, 15777–15788.
[26]
Koike, K.; Hinrichs, S.H.; Isselbacher, K.J.; Jay, G. Transgenic mouse model for human gastric carcinoma. Proc. Natl. Acad. Sci. USA 1989, 86, 5615–5619, doi:10.1073/pnas.86.14.5615.
[27]
Searle, P.F.; Thomas, D.P.; Faulkner, K.B.; Tinsley, J.M. Stomach cancer in transgenic mice expressing human papillomavirus type 16 early region genes from a keratin promoter. J. Gen. Virol. 1994, 75, 1125–1137, doi:10.1099/0022-1317-75-5-1125.
[28]
Correa, P. Human gastric carcinogenesis: A multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52, 6735–6740.
[29]
Wang, T.C.; Dangler, C.A.; Chen, D.; Goldenring, J.R.; Koh, T.; Raychowdhury, R.; Coffey, R.J.; Ito, S.; Varro, A.; Dockray, G.J.; et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000, 118, 36–47.
[30]
El-Omar, E.M.; Carrington, M.; Chow, W.H.; McColl, K.E.; Bream, J.H.; Young, H.A.; Herrera, J.; Lissowska, J.; Yuan, C.C.; Rothman, N.; et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001, 412, 99.
[31]
Quante, M.; Tu, S.P.; Tomita, H.; Gonda, T.; Wang, S.S.; Takashi, S.; Baik, G.H.; Shibata, W.; Diprete, B.; Betz, K.S.; et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19, 257–272, doi:10.1016/j.ccr.2011.01.020.
[32]
Tu, S.P.; Quante, M.; Bhagat, G.; Takaishi, S.; Cui, G.; Yang, X.D.; Muthuplani, S.; Shibata, W.; Fox, J.G.; Pritchard, D.M.; et al. IFN-γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis. Cancer Res. 2011, 71, 4247–4259, doi:10.1158/0008-5472.CAN-10-4009.
[33]
Shibata, W.; Ariyama, H.; Westphalen, C.B.; Worthley, D.L.; Muthupalani, S.; Asfaha, S.; Dubeykovskaya, Z.; Quante, M.; Fox, J.G.; Wang, T.C. Stromal cell-derived factor-1 overexpression induces gastric dysplasia through expansion of stromal myofibroblasts and epithelial progenitors. Gut 2012, 62, 192–200.
[34]
Asfaha, S.; Dubeykovskiy, A.N.; Tomita, H.; Yang, X.; Stokes, S.; Shibata, W.; Friedman, R.A.; Ariyama, H.; Dubeykovskaya, Z.A.; Muthupalani, S.; et al. Mice that Express Human Interleukin-8 Have Increased Mobilization of Immature Myeloid Cells, which Exacerbates Inflammation and Accelerates Colon Carcinogenesis. Gastroenterology 2012, 144, 155–166.
[35]
Rogers, A.B.; Fox, J.G. Inflammation and Cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G361–G366, doi:10.1152/ajpgi.00499.2003.
Ge, Z.; Feng, Y.; Muthupalani, S.; Eurell, L.L.; Taylor, N.S.; Whary, M.T.; Fox, J.G. Coinfection with Enterohepatic Helicobacter species can ameliorate or promote Helicobacter pylori-induced gastric pathology in C57BL/6 mice. Infect. Immun. 2011, 79, 3861–3871, doi:10.1128/IAI.05357-11.
[38]
Schoental, R. Carcinogenic activity of N-methyl-N-nitroso-N'-nitroguanidine. Nature 1966, 209, 726–727, doi:10.1038/209726a0.
[39]
Ohgaki, H.; Kawachi, T.; Matsukura, N.; Morino, K.; Miyamoto, M.; Sugimura, T. Genetic control of susceptibility of rats to gastric carcinoma. Cancer Res. 1983, 43, 3663–3667.
[40]
Tatematsu, M.; Yamamoto, M.; Shimizu, N.; Yoshikawa, A.; Fukami, H.; Kaminishi, M.; Oohara, T.; Sugiyama, A.; Ikeno, T. Induction of glandular stomach cancers in Helicobacter pylori-sensitive Mongolian gerbils treated with N-methyl-N-nitrosourea and N-methyl-N'-nitro-N-nitrosoguanidine in drinking water. Jpn. J. Cancer Res. 1998, 89, 97–104, doi:10.1111/j.1349-7006.1998.tb00535.x.
[41]
Takahashi, M.; Kokubo, T.; Furukawa, F.; Kurokawa, Y.; Tatematsu, M.; Hayashi, Y. Effect of high salt diet on rat gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine. Gann 1983, 74, 28–34.
[42]
Tatematsu, M.; Takahashi, M.; Fukushima, S.; Hananouchi, M.; Shirai, T. Effects in rats of sodium chloride on experimental gastric cancers induced by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline-1-oxide. J. Natl. Cancer Inst. 1975, 55, 101–106.
[43]
Tatsuta, M.; Iishi, H.; Baba, M.; Uehara, H.; Nakaizumi, A.; Taniguchi, H. Enhancing effects of calcium-deficient diet on gastric carcinogenesis by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Jpn. J. Cancer Res. 1993, 84, 945–950, doi:10.1111/j.1349-7006.1993.tb00182.x.
[44]
Wada, S.; Hirose, M.; Shichino, Y.; Ozaki, K.; Hoshiya, T.; Kato, K.; Shirai, T. Effects of catechol, sodium chloride and ethanol either alone or in combination on gastric carcinogenesis in rats pretreated with N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Lett. 1998, 123, 127–134, doi:10.1016/S0304-3835(97)00407-2.
[45]
Uedo, N.; Tatsuta, M.; Iishi, H.; Baba, M.; Yano, H.; Ishihara, R.; Higashino, K.; Ishiguro, S. Enhancement by interleukin-1 beta of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats: A possible mechanism for Helicobacter pylori-associated gastric carcinogenesis. Cancer Lett. 2003, 198, 161–168, doi:10.1016/S0304-3835(03)00342-2.
[46]
Danon, S.J.; Eaton, K.A. The role of gastric Helicobacter and N-methyl-N'-nitro-N-nitrosoguanidine in carcinogenesis of mice. Helicobacter 1998, 3, 260–268, doi:10.1046/j.1523-5378.1998.08017.x.
[47]
Tatematsu, M.; Yamamoto, M.; Iwata, H.; Fukami, H.; Yuasa, H.; Tezuka, N.; Masui, T.; Nakanishi, H. Induction of glandular stomach cancers in C3H mice treated with N-methyl-N-nitrosourea in the drinking water. Jpn. J. Cancer Res. 1993, 84, 1258–1264, doi:10.1111/j.1349-7006.1993.tb02831.x.
[48]
Yamachika, T.; Nakanishi, H.; Inada, K.; Tsukamoto, T.; Shimizu, N.; Kobayashi, K.; Fukushima, S.; Tatematsu, M. N-methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. Jpn. J. Cancer Res. 1998, 89, 385–391, doi:10.1111/j.1349-7006.1998.tb00575.x.
[49]
Yamamoto, M.; Furihata, C.; Ogiu, T.; Tsukamoto, T.; Inada, K.; Hirano, K.; Tatematsu, M. Independent variation in susceptibilities of six different mouse strains to induction of pepsinogen-altered pyloric glands and gastric tumor intestinalization by N-methyl-N-nitrosourea. Cancer Lett. 2002, 179, 121–132, doi:10.1016/S0304-3835(02)00013-7.
[50]
Yamamoto, M.; Tsukamoto, T.; Sakai, H.; Shirai, N.; Ohgaki, H.; Furihata, C.; Donehower, L.A.; Yoshida, K.; Tatematsu, M. p53 knockout mice (？/？) are more susceptible than (+/？) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis 2000, 21, 1891–1897, doi:10.1093/carcin/21.10.1891.
[51]
Sakamoto, K.; Hikiba, Y.; Nakagawa, H.; Hayakawa, Y.; Yanai, A.; Akanuma, M.; Ogura, K.; Hirata, Y.; Kaestner, K.H.; Omata, M.; et al. Inhibitor of kappaB Kinase Beta Regulates Gastric Carcinogenesis via Interleukin-1alpha Expression. Gastroenterology 2010, 139, 226–238, doi:10.1053/j.gastro.2010.03.047.
[52]
Shibata, W.; Maeda, S.; Hikiba, Y.; Yanai, A.; Sakamoto, K.; Nakagawa, H.; Ogura, K.; Karin, M.; Omata, M. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 2008, 68, 5031–5039.
[53]
Hayakawa, Y.; Hirata, Y.; Nakagawa, H.; Sakamoto, K.; Hikiba, Y.; Kinoshita, H.; Nakata, W.; Takahashi, R.; Tateishi, K.; Tada, M.; et al. Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 780–785.
[54]
Takasu, S.; Tsukamoto, T.; Cao, X.Y.; Toyoda, T.; Hirata, A.; Ban, H.; Yamamoto, M.; Sakai, H.; Yanai, T.; Masegi, T.; et al. Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogenesis in N-methyl-N-nitrosourea-treated K19-C2mE transgenic mice. Cancer Sci. 2008, 99, 2356–2364, doi:10.1111/j.1349-7006.2008.00983.x.
[55]
Leung, W.K.; Wu, K.C.; Wong, C.Y.; Cheng, A.S.; Ching, A.K.; Chan, A.W.; Chong, W.W.; Go, M.Y.; Yu, J.; To, K.F.; et al. Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis 2008, 29, 1648–1654, doi:10.1093/carcin/bgn156.
[56]
Humar, B.; Blair, V.; Charlton, A.; More, H.; Martin, I.; Guilford, P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res. 2009, 69, 2050–2056, doi:10.1158/0008-5472.CAN-08-2457.
[57]
Li, Q.; Jia, Z.; Wang, L.; Kong, X.; Guo, K.; Tan, D.; Le, X.; Wei, D.; Huang, S.; Mishra, L.; et al. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors of the antrum in mice. Gastroenterology 2012, 142, 531–542, doi:10.1053/j.gastro.2011.11.034.
[58]
Tsukamoto, T.; Mizoshita, T.; Tatematsu, M. Animal models of stomach carcinogenesis. Toxicol. Pathol. 2007, 35, 636–648, doi:10.1080/01926230701420632.
[59]
Boffa, L.C.; Bolognesi, C. Methylating agents: Their target amino acids in nuclear proteins. Carcinogenesis 1985, 6, 1399–1401, doi:10.1093/carcin/6.9.1399.
[60]
Tomita, H.; Takaishi, S.; Menheniott, T.R.; Yang, X.; Shibata, W.; Jin, G.; Betz, K.S.; Kawakami, K.; Minamoto, T.; Tomasetto, C.; et al. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology 2011, 140, 879–891, doi:10.1053/j.gastro.2010.11.037.
[61]
Cao, X.; Tsukamoto, T.; Nozaki, K.; Tanaka, H.; Shimizu, N.; Kaminishi, M.; Kumagai, T.; Tatematsu, M. Earlier Helicobacter pylori infection increases the risk for the N-methyl-N-nitrosourea-induced stomach carcinogenesis in Mongolian gerbils. Jpn. J. Cancer Res. 2002, 93, 1293–1298, doi:10.1111/j.1349-7006.2002.tb01237.x.
[62]
Maruta, F.; Sugiyama, A.; Ishida, K.; Ikeno, T.; Murakami, M.; Kawasaki, S.; Ota, H.; Tatematsu, M.; Katsuyama, T. Timing of N-methyl-N-nitrosourea administration affects gastric carcinogenesis in Mongolian gerbils infected with Helicobacter pylori. Cancer Lett. 2000, 160, 99–105, doi:10.1016/S0304-3835(00)00571-1.
[63]
Fox, J.G.; Wishnok, J.S.; Murphy, J.C.; Tannenbaum, S.R.; Correa, P. MNNG-induced gastric carcinoma in ferrets infected with Helicobacter mustelae. Carcinogenesis 1993, 14, 1957–1961, doi:10.1093/carcin/14.9.1957.
[64]
Fox, J.G. Gastric disease in ferrets: Effects of Helicobacter mustelae, nitrosamines and reconstructive gastric surgery. Eur. J. Gastroenterol. Hepatol. 1994, 6, S57–S65.
Fox, J.G.; Correa, P.; Taylor, N.S.; Lee, A.; Otto, G.; Murphy, J.C.; Rose, R. Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology 1990, 99, 352–361.
[67]
Wirth, H.P.; Beins, M.H.; Yang, M.; Tham, K.T.; Blaser, M.J. Experimental infection of Mongolian gerbils with wild-type and mutant Helicobacter pylori strains. Infect. Immun. 1998, 66, 4856–4866.
[68]
Ogura, K.; Maeda, S.; Nakao, M.; Watanabe, T.; Tada, M.; Kyutoku, T.; Yoshida, H.; Shiratori, Y.; Omata, M. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J. Exp. Med. 2000, 192, 1601–1610, doi:10.1084/jem.192.11.1601.
[69]
Israel, D.A.; Salama, N.; Arnold, C.N.; Moss, S.F.; Ando, T.; Wirth, H.P.; Tham, K.T.; Camorlinga, M.; Blaser, M.J.; Falkow, S.; et al. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. J. Clin. Invest. 2001, 107, 611–620, doi:10.1172/JCI11450.
[70]
Marchetti, M.; Rappuoli, R. Isogenic mutants of the cag pathogenicity island of Helicobacter pylori in the mouse model of infection: Effects on colonization efficiency. Microbiology 2002, 148, 1447–1456.
[71]
Ehlers, S.; Warrelmann, M.; Hahn, H. In search of an animal model for experimental Campylobacter pylori infection: Administration of Campylobacter pylori to rodents. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 1988, 268, 341–346.
[72]
Cantorna, M.T.; Balish, E. Inability of human clinical strains of Helicobacter pylori to colonize the alimentary tract of germfree rodents. Can. J. Microbiol. 1990, 36, 237–241, doi:10.1139/m90-041.
[73]
Lee, A.; Fox, J.G.; Otto, G.; Murphy, J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 1990, 99, 1315–1323.
[74]
Lee, A.; Chen, M.; Coltro, N.; O'Rourke, J.; Hazell, S.; Hu, P.; Li, Y. Long term infection of the gastric mucosa with Helicobacter species does induce atrophic gastritis in an animal model of Helicobacter pylori infection. Zentralbl Bakteriol 1993, 280, 38–50, doi:10.1016/S0934-8840(11)80939-4.
[75]
Sakagami, T.; Dixon, M.; O'Rourke, J.; Howlett, R.; Alderuccio, F.; Vella, J.; Shimoyama, T.; Lee, A. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 1996, 39, 639–648, doi:10.1136/gut.39.5.639.
Ley, C.; Mohar, A.; Guarner, J.; Herrera-Goepfert, R.; Figueroa, L.S.; Halperin, D.; Johnstone, I.; Parsonnet, J. Helicobacter pylori eradication and gastric preneoplastic conditions: A randomized, double-blind, placebo-controlled trial. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 4–10, doi:10.1158/1055-9965.EPI-03-0124.
[83]
Lee, C.W.; Rickman, B.; Rogers, A.B.; Muthupalani, S.; Takaishi, S.; Yang, P.; Wang, T.C.; Fox, J.G. Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 2009, 69, 8166–8174, doi:10.1158/0008-5472.CAN-08-3856.
[84]
Wang, X.; Willén, R.; Svensson, M.; Ljungh, A.; Wadstr？m, T. Two-year follow-up of Helicobacter pylori infection in C57BL/6 and Balb/cA mice. APMIS 2003, 111, 514–522, doi:10.1034/j.1600-0463.2003.1110410.x.
[85]
Fox, J.G.; Wang, T.C.; Rogers, A.B.; Poutahidis, T.; Ge, Z.; Taylor, N.; Dangler, C.A.; Israel, D.A.; Krishna, U.; Gaus, K.; et al. Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology 2003, 124, 1879–1890.
[86]
Higashi, H.; Tsutsumi, R.; Muto, S.; Sugiyama, T.; Azuma, T.; Asaka, M.; Hatakeyama, M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002, 295, 683–686, doi:10.1126/science.1067147.
[87]
Maeda, S.; Yoshida, H.; Ogura, K.; Mitsuno, Y.; Hirata, Y.; Yamaji, Y.; Akanuma, M.; Shiratori, Y.; Omata, M. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 2000, 119, 97–108, doi:10.1053/gast.2000.8540.
[88]
Mitsuno, Y.; Yoshida, H.; Maeda, S.; Ogura, K.; Hirata, Y.; Kawabe, T.; Shiratori, Y.; Omata, M. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. Gut 2001, 49, 18–22, doi:10.1136/gut.49.1.18.
[89]
Viala, J.; Chaput, C.; Boneca, I.G.; Cardona, A.; Girardin, S.E.; Moran, A.P.; Athman, R.; Memet, S.; Huerre, M.R.; Coyle, A.J.; et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 2004, 5, 1166–1174, doi:10.1038/ni1131.
[90]
Crabtree, J.E.; Ferrero, R.L.; Kusters, J.G. The mouse colonizing Helicobacter pylori strain SS1 may lack a functional cag pathogenicity island. Helicobacter 2002, 7, 139–140, doi:10.1046/j.1083-4389.2002.00071.x.
[91]
Ohnishi, N.; Yuasa, H.; Tanaka, S.; Sawa, H.; Miura, M.; Matsui, A.; Higashi, H.; Musashi, M.; Iwabuchi, K.; Suzuki, M.; et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc. Natl. Acad. Sci. USA 2008, 105, 1003–1008.
[92]
Arnold, I.C.; Lee, J.Y.; Amieva, M.R.; Roers, A.; Flavell, R.A.; Sparwasser, T.; Müller, A. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 2011, 140, 199–209, doi:10.1053/j.gastro.2010.06.047.
[93]
Mohammadi, M.; Redline, R.; Nedrud, J.; Czinn, S. Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains. Infect. Immun. 1996, 64, 238–245.
[94]
Ottlecz, A.; Romero, J.J.; Lichtenberger, L.M. Helicobacter infection and phospholipase A2 enzymes: Effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach. Mol. Cell. Biochem. 2001, 221, 71–77, doi:10.1023/A:1010971910866.
[95]
Roth, K.A.; Kapadia, S.B.; Martin, S.M.; Lorenz, R.G. Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. J. Immunol. 1999, 163, 1490–1497.
[96]
Eaton, K.A.; Mefford, M.; Thevenot, T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J. Immunol. 2001, 166, 7456–7461.
[97]
Smythies, L.E.; Waites, K.B.; Lindsey, J.R.; Harris, P.R.; Ghiara, P.; Smith, P.D. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J. Immunol. 2000, 165, 1022–1029.
[98]
Ismail, H.F.; Fick, P.; Zhang, J.; Lynch, R.G.; Berg, D.J. Depletion of neutrophils in IL-10？/？ mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J. Immunol. 2003, 170, 3782–3789.
[99]
Berg, D.J.; Lynch, N.A.; Lynch, R.G.; Lauricella, D.M. Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10？/？ mice. Am. J. Pathol. 1998, 152, 1377–1386.
[100]
Ohana, M.; Okazaki, K.; Oshima, C.; Andra’s, D.; Nishi, T.; Uchida, K.; Uose, S.; Nakase, H.; Matsushima, Y.; Chiba, T. A critical role for IL-7R signaling in the development of Helicobacter felis-induced gastritis in mice. Gastroenterology 2001, 121, 329–336, doi:10.1053/gast.2001.26289.
[101]
Sayi, A.; Kohler, E.; Hitzler, I.; Arnold, I.; Schwendener, R.; Rehrauer, H.; Müller, A. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J. Immunol. 2009, 182, 7085–7101.
[102]
Sayi, A.; Kohler, E.; Toller, I.M.; Flavell, R.A.; Müller, W.; Roers, A.; Müller, A. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J. Immunol. 2011, 186, 878–890, doi:10.4049/jimmunol.1002269.
Houghton, J.M.; Bloch, L.M.; Goldstein, M.; von Hagen, S.; Korah, R.M. In vivo disruption of the fas pathway abrogates gastric growth alterations secondary to Helicobacter infection. J. Infect. Dis. 2000, 182, 856–864, doi:10.1086/315788.
[105]
Shibata, W.; Takaishi, S.; Muthupalani, S.; Pritchard, D.M.; Whary, M.T.; Rogers, A.B.; Fox, J.G.; Betz, K.S.; Kaestner, K.H.; Karin, M.; et al. Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology 2010, 138, 1022–1034.e10.
[106]
Fox, J.G.; Rogers, A.B.; Ihrig, M.; Taylor, N.S.; Whary, M.T.; Dockray, G.; Varro, A.; Wang, T.C. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res. 2003, 63, 942–950.
[107]
Sheh, A.; Lee, C.W.; Masumura, K.; Rickman, B.H.; Nohmi, T.; Wogan, G.N.; Fox, J.G.; Schauer, D.B. Mutagenic potency of Helicobacter pylori in the gastric mucosa of mice is determined by sex and duration of infection. Proc. Natl. Acad. Sci. USA 2010, 107, 15217–15222.
[108]
Crabtree, J.E.; Court, M.; Aboshkiwa, M.A.; Jeremy, A.H.; Dixon, M.F.; Robinson, P.A. Gastric mucosal cytokine and epithelial cell responses to Helicobacter pylori infection in Mongolian gerbils. J. Pathol. 2004, 202, 197–207, doi:10.1002/path.1498.
[109]
Shimizu, N.; Kaminishi, M.; Tatematsu, M.; Tsuji, E.; Yoshikawa, A.; Yamaguchi, H.; Aoki, F.; Oohara, T. Helicobacter pylori promotes development of pepsinogen-altered pyloric glands, a preneoplastic lesion of glandular stomach of BALB/c mice pretreated with N-methyl-N-nitrosourea. Cancer Lett. 1998, 123, 63–69, doi:10.1016/S0304-3835(97)00405-9.
[110]
Han, S.U.; Kim, Y.B.; Joo, H.J.; Hahm, K.B.; Lee, W.H.; Cho, Y.K.; Kim, D.Y.; Kim, M.W. Helicobacter pylori infection promotes gastric carcinogenesis in a mice model. J. Gastroenterol. Hepatol. 2002, 17, 253–261, doi:10.1046/j.1440-1746.2002.02684.x.
[111]
Fox, J.G.; Dangler, C.A.; Taylor, N.S.; King, A.; Koh, T.J.; Wang, T.C. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res. 1999, 59, 4823–4828.
Varon, C.; Dubus, P.; Mazurier, F.; Asencio, C.; Chambonnier, L.; Ferrand, J.; Giese, A.; Senant-Dugot, N.; Carlotti, M.; Mégraud, F. Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology 2012, 142, 281–291, doi:10.1053/j.gastro.2011.10.036.
[116]
Worthley, D.L.; Giraud, A.S.; Wang, T.C. Stromal fibroblasts in digestive cancer. Cancer Microenviron 2010, 3, 117–125, doi:10.1007/s12307-009-0033-8.
[117]
Rindi, G.; Bordi, C.; Rappel, S.; La Rosa, S.; Stolte, M.; Solcia, E. Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology, and behavior. World J. Surg. 1996, 20, 168–172, doi:10.1007/s002689900026.
[118]
Ferrand, A.; Wang, T.C. Gastrin and cancer: A review. Cancer Lett. 2006, 238, 15–29, doi:10.1016/j.canlet.2005.06.025.
[119]
Wang, T.C.; Brand, S.J. Function and regulation of gastrin in transgenic mice: A review. Yale J. Biol. Med. 1992, 65, 705–740.
Takaishi, S.; Tu, S.; Dubeykovskaya, Z.A.; Whary, M.T.; Muthupalani, S.; Rickman, B.H.; Rogers, A.B.; Lertkowit, N.; Varro, A.; Fox, J.G.; et al. Gastrin is an essential cofactor for helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice. Am. J. Pathol. 2009, 175, 365–375, doi:10.2353/ajpath.2009.081165.
[124]
Cui, G.; Koh, T.J.; Chen, D.; Zhao, C.M.; Takaishi, S.; Dockray, G.J.; Varro, A.; Rogers, A.B.; Fox, J.G.; Wang, T.C. Overexpression of glycine-extended gastrin inhibits parietal cell loss and atrophy in the mouse stomach. Cancer Res. 2004, 64, 8160–8166.
[125]
Takaishi, S.; Wang, T.C. Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. Cancer Sci. 2007, 98, 284–293, doi:10.1111/j.1349-7006.2007.00392.x.
[126]
Tu, S.; Chi, A.L.; Lim, S.; Cui, G.; Dubeykovskaya, Z.; Ai, W.; Fleming, J.V.; Takaishi, S.; Wang, T.C. Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G1726–G1737, doi:10.1152/ajpgi.00348.2006.
[127]
Steele, I.A.; Dimaline, R.; Pritchard, D.M.; Peek, R.M.; Wang, T.C.; Dockray, G.J.; Varro, A. Helicobacter and gastrin stimulate Reg1 expression in gastric epithelial cells through distinct promoter elements. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G347–G354, doi:10.1152/ajpgi.00076.2007.
[128]
Yin, Y.; Grabowska, A.M.; Clarke, P.A.; Whelband, E.; Robinson, K.; Argent, R.H.; Tobias, A.; Kumari, R.; Atherton, J.C.; Watson, S.A. Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: Links to soluble HB-EGF, gastrin and matrix metalloproteinase-7. Gut 2010, 59, 1037–1045.
[129]
Takaishi, S.; Cui, G.; Frederick, D.M.; Carlson, J.E.; Houghton, J.; Varro, A.; Dockray, G.J.; Ge, Z.; Whary, M.T.; Rogers, A.B.; et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005, 128, 1965–1983, doi:10.1053/j.gastro.2005.03.027.
[130]
Okabe, S.; Kodama, Y.; Cao, H.; Johannessen, H.; Zhao, C.M.; Wang, T.C.; Takahashi, R.; Chen, D. Topical application of acetic acid in cytoreduction of gastric cancer. A technical report using mouse model. J. Gastroenterol. Hepatol. 2012, 27, 40–48, doi:10.1111/j.1440-1746.2012.07070.x.
[131]
Ohtani, M.; García, A.; Rogers, A.B.; Ge, Z.; Taylor, N.S.; Xu, S.; Watanabe, K.; Marini, R.P.; Whary, M.T.; Wang, T.C.; et al. Protective role of 17 beta-estradiol against the development of Helicobacter pylori-induced gastric cancer in INS-GAS mice. Carcinogenesis 2007, 28, 2597–2604, doi:10.1093/carcin/bgm150.
[132]
Ohtani, M.; Ge, Z.; García, A.; Rogers, A.B.; Muthupalani, S.; Taylor, N.S.; Xu, S.; Watanabe, K.; Feng, Y.; Marini, R.P.; et al. 17 β-estradiol suppresses Helicobacter pylori-induced gastric pathology in male hypergastrinemic INS-GAS mice. Carcinogenesis 2011, 32, 1244–1250, doi:10.1093/carcin/bgr072.
[133]
Sheh, A.; Ge, Z.; Parry, N.M.; Muthupalani, S.; Rager, J.E.; Raczynski, A.R.; Mobley, M.W.; McCabe, A.F.; Fry, R.C.; Wang, T.C.; et al. 17β-estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice. Cancer Prev. Res. (Phila.) 2011, 4, 1426–1435, doi:10.1158/1940-6207.CAPR-11-0219.
[134]
Stenstr？m, B.; Zhao, C.M.; Rogers, A.B.; Nilsson, H.O.; Stureg？rd, E.; Lundgren, S.; Fox, J.G.; Wang, T.C.; Wadstr？m, T.M.; Chen, D. Swedish moist snuff accelerates gastric cancer development in Helicobacter pylori-infected wild-type and gastrin transgenic mice. Carcinogenesis 2007, 28, 2041–2046, doi:10.1093/carcin/bgm071.
Singh, P.; Velasco, M.; Given, R.; Wargovich, M.; Varro, A.; Wang, T.C. Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt foci in response to AOM. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278, G390–G399.
[138]
Singh, P.; Velasco, M.; Given, R.; Varro, A.; Wang, T.C. Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen. Gastroenterology 2000, 119, 162–171, doi:10.1053/gast.2000.8527.
Zavros, Y.; Rieder, G.; Ferguson, A.; Samuelson, L.C.; Merchant, J.L. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology 2002, 122, 119–133, doi:10.1053/gast.2002.30298.
[143]
Zavros, Y.; Eaton, K.A.; Kang, W.; Rathinavelu, S.; Katukuri, V.; Kao, J.Y.; Samuelson, L.C.; Merchant, J.L. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene 2005, 24, 2354–2366.
[144]
Lefebvre, O.; Chenard, M.P.; Masson, R.; Linares, J.; Dierich, A.; LeMeur, M.; Wendling, C.; Tomasetto, C.; Chambon, P.; Rio, M.C. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996, 274, 259–262, doi:10.1126/science.274.5285.259.
[145]
Soutto, M.; Belkhiri, A.; Piazuelo, M.B.; Schneider, B.G.; Peng, D.; Jiang, A.; Washington, M.K.; Kokoye, Y.; Crowe, S.E.; Zaika, A.; et al. Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J. Clin. Invest. 2011, 121, 1753–1767, doi:10.1172/JCI43922.
[146]
Beckler, A.D.; Roche, J.K.; Harper, J.C.; Petroni, G.; Frierson, H.F.; Moskaluk, C.A.; El-Rifai, W.; Powell, S.M. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer 2003, 98, 2184–2191, doi:10.1002/cncr.11789.
[147]
Fujimoto, J.; Yasui, W.; Tahara, H.; Tahara, E.; Kudo, Y.; Yokozaki, H. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett. 2000, 149, 125–134, doi:10.1016/S0304-3835(99)00349-3.
[148]
Carvalho, R.; Kayademir, T.; Soares, P.; Canedo, P.; Sousa, S.; Oliveira, C.; Leistenschneider, P.; Seruca, R.; G？tt, P.; Blin, N.; et al. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab. Invest. 2002, 82, 1319–1326.
[149]
Khan, Z.E.; Wang, T.C.; Cui, G.; Chi, A.L.; Dimaline, R. Transcriptional regulation of the human trefoil factor, TFF1, by gastrin. Gastroenterology 2003, 125, 510–521, doi:10.1016/S0016-5085(03)00908-9.
[150]
Clyne, M.; Dillon, P.; Daly, S.; O'Kennedy, R.; May, F.E.; Westley, B.R.; Drumm, B. Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. Proc. Natl. Acad. Sci. USA 2004, 101, 7409–7414.
[151]
Reeves, E.P.; Ali, T.; Leonard, P.; Hearty, S.; O'Kennedy, R.; May, F.E.; Westley, B.R.; Josenhans, C.; Rust, M.; Suerbaum, S.; et al. Helicobacter pylori lipopolysaccharide interacts with TFF1 in a pH-dependent manner. Gastroenterology 2008, 135, 2043–2054.e2, doi:10.1053/j.gastro.2008.08.049.
[152]
Rio, M.C.; Bellocq, J.P.; Daniel, J.Y.; Tomasetto, C.; Lathe, R.; Chenard, M.P.; Batzenschlager, A.; Chambon, P. Breast cancer-associated pS2 protein: Synthesis and secretion by normal stomach mucosa. Science 1988, 241, 705–708.
[153]
Hanby, A.M.; Poulsom, R.; Singh, S.; Elia, G.; Jeffery, R.E.; Wright, N.A. Spasmolytic polypeptide is a major antral peptide: Distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology 1993, 105, 1110–1116.
[154]
Hanby, A.M.; Poulsom, R.; Elia, G.; Singh, S.; Longcroft, J.M.; Wright, N.A. The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in “gastric metaplasia” of the proximal duodenum: Implications for the nature of “gastric metaplasia”. J. Pathol. 1993, 169, 355–360, doi:10.1002/path.1711690313.
[155]
Farrell, J.J.; Taupin, D.; Koh, T.J.; Chen, D.; Zhao, C.M.; Podolsky, D.K.; Wang, T.C. TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J. Clin. Invest. 2002, 109, 193–204.
[156]
Fox, J.G.; Rogers, A.B.; Whary, M.T.; Ge, Z.; Ohtani, M.; Jones, E.K.; Wang, T.C. Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2？/？ C57BL6 × Sv129 Helicobacter pylori-infected mice. Am. J. Pathol. 2007, 171, 1520–1528, doi:10.2353/ajpath.2007.070249.
[157]
Peterson, A.J.; Menheniott, T.R.; O'Connor, L.; Walduck, A.K.; Fox, J.G.; Kawakami, K.; Minamoto, T.; Ong, E.K.; Wang, T.C.; Judd, L.M.; et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology 2010, 139, 2005–2017, doi:10.1053/j.gastro.2010.08.043.
[158]
Jenkins, B.J.; Grail, D.; Nheu, T.; Najdovska, M.; Wang, B.; Waring, P.; Inglese, M.; McLoughlin, R.M.; Jones, S.A.; Topley, N.; et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat. Med. 2005, 11, 845–852.
[159]
Tebbutt, N.C.; Giraud, A.S.; Inglese, M.; Jenkins, B.; Waring, P.; Clay, F.J.; Malki, S.; Alderman, B.M.; Grail, D.; Hollande, F.; et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 2002, 8, 1089–1097.
Judd, L.M.; Ulaganathan, M.; Howlett, M.; Giraud, A.S. Cytokine signalling by gp130 regulates gastric mucosal healing after ulceration and, indirectly, antral tumour progression. J. Pathol. 2009, 217, 552–562, doi:10.1002/path.2479.
[162]
Ernst, M.; Najdovska, M.; Grail, D.; Lundgren-May, T.; Buchert, M.; Tye, H.; Matthews, V.B.; Armes, J.; Bhathal, P.S.; Hughes, N.R.; et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 2008, 118, 1727–1738.
[163]
Tu, S.; Bhagat, G.; Cui, G.; Takaishi, S.; Kurt-Jones, E.A.; Rickman, B.; Betz, K.S.; Penz-Oesterreicher, M.; Bjorkdahl, O.; Fox, J.G.; et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14, 408–419, doi:10.1016/j.ccr.2008.10.011.
[164]
Song, X.; Krelin, Y.; Dvorkin, T.; Bjorkdahl, O.; Segal, S.; Dinarello, C.A.; Voronov, E.; Apte, R.N. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005, 175, 8200–8208.
[165]
Waghray, M.; Zavros, Y.; Saqui-Salces, M.; El-Zaatari, M.; Alamelumangapuram, C.B.; Todisco, A.; Eaton, K.A.; Merchant, J.L. Interleukin-1beta promotes gastric atrophy through suppression of Sonic Hedgehog. Gastroenterology 2010, 138, 562–572.e2.
[166]
Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res. 1989, 49, 4682–4689.
[167]
Ellis, C.A.; Clark, G. The importance of being K-Ras. Cell. Signal. 2000, 12, 425–434, doi:10.1016/S0898-6568(00)00084-X.
[168]
Ushijima, T.; Sasako, M. Focus on gastric cancer. Cancer Cell 2004, 5, 121–125, doi:10.1016/S1535-6108(04)00033-9.
[169]
Frame, S.; Balmain, A. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr. Opin. Genet. Dev. 2000, 10, 106–113, doi:10.1016/S0959-437X(99)00052-0.
[170]
Hingorani, S.R.; Petricoin, E.F.; Maitra, A.; Rajapakse, V.; King, C.; Jacobetz, M.A.; Ross, S.; Conrads, T.P.; Veenstra, T.D.; Hitt, B.A.; et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4, 437–450, doi:10.1016/S1535-6108(03)00309-X.
[171]
Brembeck, F.H.; Schreiber, F.S.; Deramaudt, T.B.; Craig, L.; Rhoades, B.; Swain, G.; Grippo, P.; Stoffers, D.A.; Silberg, D.G.; Rustgi, A.K. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 2003, 63, 2005–2009.
[172]
Okumura, T.; Ericksen, R.E.; Takaishi, S.; Wang, S.S.; Dubeykovskiy, Z.; Shibata, W.; Betz, K.S.; Muthupalani, S.; Rogers, A.B.; Fox, J.G.; et al. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. Cancer Res. 2010, 70, 8435–8445.
[173]
Ray, K.C.; Bell, K.M.; Yan, J.; Gu, G.; Chung, C.H.; Washington, M.K.; Means, A.L. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One 2011, 6, e16786.
[174]
Matkar, S.S.; Durham, A.; Brice, A.; Wang, T.C.; Rustgi, A.K.; Hua, X. Systemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in mice. Am. J. Cancer Res. 2011, 1, 432–445.
[175]
Park, W.S.; Oh, R.R.; Park, J.Y.; Lee, S.H.; Shin, M.S.; Kim, Y.S.; Kim, S.Y.; Lee, H.K.; Kim, P.J.; Oh, S.T.; et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999, 59, 4257–4260.
[176]
Park, J.G.; Park, K.J.; Ahn, Y.O.; Song, I.S.; Choi, K.W.; Moon, H.Y.; Choo, S.Y.; Kim, J.P. Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis. Colon Rectum. 1992, 35, 996–998, doi:10.1007/BF02253505.
[177]
Abraham, S.C.; Nobukawa, B.; Giardiello, F.M.; Hamilton, S.R.; Wu, T.T. Fundic gland polyps in familial adenomatous polyposis: Neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am. J. Pathol. 2000, 157, 747–754.
[178]
Fox, J.G.; Dangler, C.A.; Whary, M.T.; Edelman, W.; Kucherlapati, R.; Wang, T.C. Mice carrying a truncated Apc gene have diminished gastric epithelial proliferation, gastric inflammation, and humoral immunity in response to Helicobacter felis infection. Cancer Res. 1997, 57, 3972–3978.
[179]
Oshima, H.; Matsunaga, A.; Fujimura, T.; Tsukamoto, T.; Taketo, M.M.; Oshima, M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 2006, 131, 1086–1095, doi:10.1053/j.gastro.2006.07.014.
[180]
Ristim？ki, A.; Honkanen, N.; J？nk？l？, H.; Sipponen, P.; H？rk？nen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997, 57, 1276–1280.
[181]
Hu, P.J.; Yu, J.; Zeng, Z.R.; Leung, W.K.; Lin, H.L.; Tang, B.D.; Bai, A.H.; Sung, J.J. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004, 53, 195–200, doi:10.1136/gut.2003.021477.
[182]
Lee, C.W.; Rickman, B.; Rogers, A.B.; Muthupalani, S.; Takaishi, S.; Yang, P.; Wang, T.C.; Fox, J.G. Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 2009, 69, 8166–8174.
[183]
Xiao, F.; Furuta, T.; Takashima, M.; Shirai, N.; Hanai, H. Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice. Scand. J. Gastroenterol. 2001, 36, 577–583, doi:10.1080/00365520117925.
[184]
Xiao, F.; Furuta, T.; Takashima, M.; Shirai, N.; Hanai, H. Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice. Aliment. Pharmacol. Ther. 2001, 15, 875–886, doi:10.1046/j.1365-2036.2001.00965.x.
[185]
Hahm, K.B.; Song, Y.J.; Oh, T.Y.; Lee, J.S.; Surh, Y.J.; Kim, Y.B.; Yoo, B.M.; Kim, J.H.; Han, S.U.; Nahm, K.T.; et al. Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: Is it possible? J. Biochem. Mol. Biol. 2003, 36, 82–94, doi:10.5483/BMBRep.2003.36.1.082.
[186]
Oshima, H.; Oshima, M.; Inaba, K.; Taketo, M.M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004, 23, 1669–1678, doi:10.1038/sj.emboj.7600170.
[187]
Oshima, M.; Oshima, H.; Matsunaga, A.; Taketo, M.M. Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice. Cancer Res. 2005, 65, 9147–9151, doi:10.1158/0008-5472.CAN-05-1936.
[188]
Takaishi, S.; Okumura, T.; Tu, S.; Wang, S.S.; Shibata, W.; Vigneshwaran, R.; Gordon, S.A.; Shimada, Y.; Wang, T.C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27, 1006–1020, doi:10.1002/stem.30.
[189]
Ishimoto, T.; Nagano, O.; Yae, T.; Tamada, M.; Motohara, T.; Oshima, H.; Oshima, M.; Ikeda, T.; Asaba, R.; Yagi, H.; et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19, 387–400, doi:10.1016/j.ccr.2011.01.038.
[190]
Markowitz, S.D.; Roberts, A.B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996, 7, 93–102.
[191]
Yang, H.K.; Kang, S.H.; Kim, Y.S.; Won, K.; Bang, Y.J.; Kim, S.J. Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells. Oncogene 1999, 18, 2213–2219, doi:10.1038/sj.onc.1202535.
[192]
Wu, M.S.; Lee, C.W.; Shun, C.T.; Wang, H.P.; Lee, W.J.; Chang, M.C.; Sheu, J.C.; Lin, J.T. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer 2000, 27, 403–411, doi:10.1002/(SICI)1098-2264(200004)27:4<403::AID-GCC10>3.0.CO;2-1.
[193]
Crawford, S.E.; Stellmach, V.; Murphy-Ullrich, J.E.; Ribeiro, S.M.; Lawler, J.; Hynes, R.O.; Boivin, G.P.; Bouck, N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998, 93, 1159–1170, doi:10.1016/S0092-8674(00)81460-9.
[194]
Hahm, K.B.; Lee, K.M.; Kim, Y.B.; Hong, W.S.; Lee, W.H.; Han, S.U.; Kim, M.W.; Ahn, B.O.; Oh, T.Y.; Lee, M.H.; et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment. Pharmacol. Ther. 2002, 16, 115–127.
[195]
Xu, X.; Brodie, S.G.; Yang, X.; Im, Y.H.; Parks, W.T.; Chen, L.; Zhou, Y.X.; Weinstein, M.; Kim, S.J.; Deng, C.X. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 2000, 19, 1868–1874, doi:10.1038/sj.onc.1203504.
[196]
Takaku, K.; Miyoshi, H.; Matsunaga, A.; Oshima, M.; Sasaki, N.; Taketo, M.M. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 1999, 59, 6113–6117.
[197]
Hahn, J.N.; Falck, V.G.; Jirik, F.R. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J. Clin. Invest. 2011, 121, 4030–4042, doi:10.1172/JCI45114.
[198]
Kim, B.G.; Li, C.; Qiao, W.; Mamura, M.; Kasprzak, B.; Kasperczak, B.; Anver, M.; Wolfraim, L.; Hong, S.; Mushinski, E.; et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006, 441, 1015–1019.
[199]
Tsuzuki, T.; Egashira, A.; Igarashi, H.; Iwakuma, T.; Nakatsuru, Y.; Tominaga, Y.; Kawate, H.; Nakao, K.; Nakamura, K.; Ide, F.; et al. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. Proc. Natl. Acad. Sci. USA 2001, 98, 11456–11461.
[200]
Shimada, S.; Mimata, A.; Sekine, M.; Mogushi, K.; Akiyama, Y.; Fukamachi, H.; Jonkers, J.; Tanaka, H.; Eishi, Y.; Yuasa, Y. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 2012, 61, 344–353.
[201]
Ito, K.; Chuang, L.S.; Ito, T.; Chang, T.L.; Fukamachi, H.; Salto-Tellez, M.; Ito, Y. Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology 2011, 140, 1536–1546.e8, doi:10.1053/j.gastro.2011.01.043.
[202]
Ito, K.; Liu, Q.; Salto-Tellez, M.; Yano, T.; Tada, K.; Ida, H.; Huang, C.; Shah, N.; Inoue, M.; Rajnakova, A.; et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res. 2005, 65, 7743–7750.
[203]
Li, Q.L.; Ito, K.; Sakakura, C.; Fukamachi, H.; Inoue, K.; Chi, X.Z.; Lee, K.Y.; Nomura, S.; Lee, C.W.; Han, S.B.; et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109, 113–124, doi:10.1016/S0092-8674(02)00690-6.
Jenks, P.J.; Jeremy, A.H.; Robinson, P.A.; Walker, M.M.; Crabtree, J.E. Long-term infection with Helicobacter felis and inactivation of the tumour suppressor gene p53 cumulatively enhance the gastric mutation frequency in Big Blue transgenic mice. J. Pathol. 2003, 201, 596–602, doi:10.1002/path.1488.
[207]
Ohgaki, H.; Fukuda, M.; Tohma, Y.; Huang, H.; Stoica, G.; Tatematsu, M.; Donehower, L.A. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol. Carcinog. 2000, 28, 97–101, doi:10.1002/1098-2744(200006)28:2<97::AID-MC5>3.0.CO;2-O.
[208]
Suzuki, H.; Miyazawa, M.; Kai, A.; Suzuki, M.; Suematsu, M.; Miura, S.; Ishii, H. No difference in the level of gastric mucosal cell apoptosis and proliferation in Helicobacter pylori-colonized p53 heterozygous knockout mice. Aliment. Pharmacol. Ther. 2002, 16, 158–166, doi:10.1046/j.1365-2036.16.s2.18.x.
[209]
Wei, D.; Gong, W.; Kanai, M.; Schlunk, C.; Wang, L.; Yao, J.C.; Wu, T.T.; Huang, S.; Xie, K. Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005, 65, 2746–2754.
[210]
Becker, K.F.; Atkinson, M.J.; Reich, U.; Becker, I.; Nekarda, H.; Siewert, J.R.; H？fler, H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994, 54, 3845–3852.
[211]
Tamura, G.; Yin, J.; Wang, S.; Fleisher, A.S.; Zou, T.; Abraham, J.M.; Kong, D.; Smolinski, K.N.; Wilson, K.T.; James, S.P.; et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J. Natl. Cancer Inst. 2000, 92, 569–573, doi:10.1093/jnci/92.7.569.
Takagi, H.; Fukusato, T.; Kawaharada, U.; Kuboyama, S.; Merlino, G.; Tsutsumi, Y. Histochemical analysis of hyperplastic stomach of TGF-alpha transgenic mice. Dig. Dis. Sci. 1997, 42, 91–98, doi:10.1023/A:1018837121947.
[214]
Li, Q.; Karam, S.M.; Gordon, J.I. Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. J. Biol. Chem. 1996, 271, 3671–3676.
[215]
Canfield, V.; West, A.B.; Goldenring, J.R.; Levenson, R. Genetic ablation of parietal cells in transgenic mice: A new model for analyzing cell lineage relationships in the gastric mucosa. Proc. Natl. Acad. Sci. USA 1996, 93, 2431–2435.
[216]
Spicer, Z.; Miller, M.L.; Andringa, A.; Riddle, T.M.; Duffy, J.J.; Doetschman, T.; Shull, G.E. Stomachs of mice lacking the gastric H,K-ATPase alpha -subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia. J. Biol. Chem. 2000, 275, 21555–21565.
[217]
Scarff, K.L.; Judd, L.M.; Toh, B.H.; Gleeson, P.A.; van Driel, I.R. Gastric H(+),K(+)-adenosine triphosphatase beta subunit is required for normal function, development, and membrane structure of mouse parietal cells. Gastroenterology 1999, 117, 605–618, doi:10.1016/S0016-5085(99)70453-1.
[218]
Franic, T.V.; Judd, L.M.; Robinson, D.; Barrett, S.P.; Scarff, K.L.; Gleeson, P.A.; Samuelson, L.C.; van Driel, I.R. Regulation of gastric epithelial cell development revealed in H(+)/K(+)-ATPase beta-subunit- and gastrin-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281, G1502–G1511.
[219]
Schultheis, P.J.; Clarke, L.L.; Meneton, P.; Harline, M.; Boivin, G.P.; Stemmermann, G.; Duffy, J.J.; Doetschman, T.; Miller, M.L.; Shull, G.E. Targeted disruption of the murine Na+/H+ exchanger isoform 2 gene causes reduced viability of gastric parietal cells and loss of net acid secretion. J. Clin. Invest. 1998, 101, 1243–1253, doi:10.1172/JCI1249.
[220]
Gut, M.O.; Parkkila, S.; Vernerová, Z.; Rohde, E.; Závada, J.; H？cker, M.; Pastorek, J.; Karttunen, T.; Gibadulinová, A.; Závadová, Z.; et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002, 123, 1889–1903, doi:10.1053/gast.2002.37052.
[221]
Nagata, A.; Ito, M.; Iwata, N.; Kuno, J.; Takano, H.; Minowa, O.; Chihara, K.; Matsui, T.; Noda, T. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. Sci. USA 1996, 93, 11825–11830.
[222]
Langhans, N.; Rindi, G.; Chiu, M.; Rehfeld, J.F.; Ardman, B.; Beinborn, M.; Kopin, A.S. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 1997, 112, 280–286, doi:10.1016/S0016-5085(97)90000-7.
[223]
Xiao, C.; Ogle, S.A.; Schumacher, M.A.; Orr-Asman, M.A.; Miller, M.L.; Lertkowit, N.; Varro, A.; Hollande, F.; Zavros, Y. Loss of parietal cell expression of Sonic hedgehog induces hypergastrinemia and hyperproliferation of surface mucous cells. Gastroenterology 2010, 138, 550–561.e8.
Goldenring, J.R.; Nomura, S. Differentiation of the gastric mucosa III. Animal models of oxyntic atrophy and metaplasia. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G999–G1004, doi:10.1152/ajpgi.00187.2006.
[232]
Hattori, T. Development of adenocarcinomas in the stomach. Cancer 1986, 57, 1528–1534, doi:10.1002/1097-0142(19860415)57:8<1528::AID-CNCR2820570815>3.0.CO;2-3.
[233]
Goldenring, J.R.; Wang, T.C.; Mills, J.C.; Wright, N.A. Spasmolytic polypeptide-expressing metaplasia: Time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010, 138, 2207–2210.
[234]
Barker, N.; van Es, J.H.; Kuipers, J.; Kujala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters, P.J.; et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449, 1003–1007, doi:10.1038/nature06196.
[235]
Powell, A.E.; Wang, Y.; Li, Y.; Poulin, E.J.; Means, A.L.; Washington, M.K.; Higginbotham, J.N.; Juchheim, A.; Prasad, N.; Levy, S.E.; et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012, 149, 146–158, doi:10.1016/j.cell.2012.02.042.
[236]
Arnold, K.; Sarkar, A.; Yram, M.A.; Polo, J.M.; Bronson, R.; Sengupta, S.; Seandel, M.; Geijsen, N.; Hochedlinger, K. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell 2011, 9, 317–329, doi:10.1016/j.stem.2011.09.001.
[237]
Furuyama, K.; Kawaguchi, Y.; Akiyama, H.; Horiguchi, M.; Kodama, S.; Kuhara, T.; Hosokawa, S.; Elbahrawy, A.; Soeda, T.; Koizumi, M.; et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat. Genet. 2011, 43, 34–41, doi:10.1038/ng.722.
[238]
Sangiorgi, E.; Capecchi, M.R. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 2008, 40, 915–920, doi:10.1038/ng.165.
[239]
Takeda, N.; Jain, R.; LeBoeuf, M.R.; Wang, Q.; Lu, M.M.; Epstein, J.A. Interconversion between intestinal stem cell populations in distinct niches. Science 2011, 334, 1420–1424, doi:10.1126/science.1213214.
[240]
Barker, N.; Huch, M.; Kujala, P.; van de Wetering, M.; Snippert, H.J.; van Es, J.H.; Sato, T.; Stange, D.E.; Begthel, H.; van den Born, M.; et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010, 6, 25–36, doi:10.1016/j.stem.2009.11.013.
Sakamoto, H.; Yoshimura, K.; Saeki, N.; Katai, H.; Shimoda, T.; Matsuno, Y.; Saito, D.; Sugimura, H.; Tanioka, F.; Kato, S.; et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 2008, 40, 730–740, doi:10.1038/ng.152.
[246]
Shi, Y.; Hu, Z.; Wu, C.; Dai, J.; Li, H.; Dong, J.; Wang, M.; Miao, X.; Zhou, Y.; Lu, F.; et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.3.31 and 5p13.1. Nat. Genet. 2011, 43, 1215–1218, doi:10.1038/ng.978.
[247]
Abnet, C.C.; Freedman, N.D.; Hu, N.; Wang, Z.; Yu, K.; Shu, X.O.; Yuan, J.M.; Zheng, W.; Dawsey, S.M.; Dong, L.M.; et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat. Genet. 2010, 42, 764–767, doi:10.1038/ng.649.
